AIM
CARM

Advantage Investment Management’s Carisma Therapeutics CARM Stock Holding History

Advantage Investment Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50
Closed -$1K – 956
2018
Q1 		$1K Hold
50
– – ﹤0.01% 939
2017
Q4 		$1K Hold
50
– – ﹤0.01% 948
2017
Q3 		$2K Hold
50
– – ﹤0.01% 932
2017
Q2 		$2K Hold
50
– – ﹤0.01% 946
2017
Q1 		$2K Hold
50
– – ﹤0.01% 891
2016
Q4 		$2K Hold
50
– – ﹤0.01% 839
2016
Q3 		$3K Buy
+50
New +$3.72K ﹤0.01% 783

Other funds holding CARM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Advantage Investment Management's CARM Position: Q2 2018 in Review

Advantage Investment Management sold out of Carisma Therapeutics (CARM) in Q2 2018, closing a stake of 50 shares — an estimated $1K sold.

Advantage Investment Management first reported a position in CARM in Q3 2016 and held it in 7 quarters. The position peaked at $3K in Q3 2016. 46 funds tracked by Wall St. Rank hold CARM as of Q2 2018.

  • Advantage Investment Management reported no remaining Carisma Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Advantage Investment Management sold 50 Carisma Therapeutics shares in Q2 2018, an estimated $1K.
  • Advantage Investment Management first reported a position in Carisma Therapeutics in Q3 2016 and held it in 7 quarters.
  • Advantage Investment Management's Carisma Therapeutics position peaked at $3K in Q3 2016.
  • 46 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2018.

Based on Advantage Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.